| CAPRICOR THERAPEUTICS |
| USA |
| Gesundheit |
| US14070B3096 / A2PLU4 |
| 4LN2 (Frankfurt) / CAPR (NASDAQ) |
| FRA:4LN2, ETR:4LN2, 4LN2:GR, NASDAQ:CAPR |
| - |
| https://capricor.com/ |
|
Capricor Therapeutics Inc. is a clinical-stage biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases with high unmet medical need. The company concentrates particularly on Duchenne muscular dystrophy, targe..
>Volltext.. |
| 210.55 Mio. EUR |
| -12.31 Mio. EUR |
| - |
| -102.32 Mio. EUR |
| -99.44 Mio. EUR |
| -2.01 EUR |
| 18.33 Mio. EUR |
| 91.48 Mio. EUR |
| -80.38 Mio. EUR |
| 8.28 |
| -100% |
| -94.86% |
| - |
| - |
| - |
| - |
| CAPRICOR THERAPEUTICS, CAPRICOR THERAPEUTIC |
| 03.08.26 |
|
||||
|